Gufic Biosciences Ltd
GUFICBIOGufic Biosciences Ltd
GUFICBIO
Price Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 52.07 | 8.30 | 0.02% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.53 | 6.56 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Gufic Biosciences Limited manufactures pharmaceuticals, medicinal chemicals and botanical products. The Company's segments include Formulations, Bulk Drugs and Consumer.
Investor Presentation
View olderPeers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2024 | TTM | ||
|---|---|---|---|---|
| Total Revenue | 808.85 | 806.43 | ||
Raw Materials | 389.32 | 658.68 | ||
| Power & Fuel Cost | 17.79 | |||
| Employee Cost | 109.63 | |||
| Selling & Administrative Expenses | 103.90 | |||
| Operating & Other expenses | 40.15 | |||
EBITDA | 148.06 | 147.75 | ||
| Depreciation/Amortization | 17.02 | 17.09 | ||
| PBIT | 131.04 | 130.66 | ||
| Interest & Other Items | 15.36 | 16.63 | ||
| PBT | 115.68 | 114.03 | ||
| Taxes & Other Items | 29.54 | 29.11 | ||
| Net Income | 86.14 | 84.92 | ||
| EPS | 8.59 | 8.47 | ||
| DPS | 0.10 | 0.10 | ||
| Payout ratio | 0.01 | 0.01 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFInvestor Presentation
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Gufic Biosciences Ltd | 51.33 | 8.30 | 0.02% |
| Sun Pharmaceutical Industries Ltd | 45.35 | 6.47 | 0.75% |
| Cipla Ltd | 28.51 | 4.38 | 0.89% |
| Torrent Pharmaceuticals Ltd | 68.45 | 16.54 | 0.84% |
Price Comparison
Compare GUFICBIO with any stock or ETFShareholdings
Promoter Holdings Trend
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Gufic Biosciences Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
Motilal Oswal Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.9745% | Percentage of the fund’s portfolio invested in the stock 1.36% | Change in the portfolio weight of the stock over the last 3 months -0.43% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 43/49 (-7) |
SBI Healthcare Opportunities Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.9364% | Percentage of the fund’s portfolio invested in the stock 1.20% | Change in the portfolio weight of the stock over the last 3 months -0.06% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 27/34 (0) |
Bank of India Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.3150% | Percentage of the fund’s portfolio invested in the stock 0.86% | Change in the portfolio weight of the stock over the last 3 months 0.86% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 80/84 (-1) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 17, 2024
Dividend/Share
₹0.10
Ex DateEx Date
Sep 17, 2024
Cash Dividend
Ex DateEx DateSep 21, 2023
Dividend/Share
₹0.10
Ex DateEx Date
Sep 21, 2023
Cash Dividend
Ex DateEx DateAug 24, 2022
Dividend/Share
₹0.10
Ex DateEx Date
Aug 24, 2022
Cash Dividend
Ex DateEx DateSep 9, 2021
Dividend/Share
₹0.10
Ex DateEx Date
Sep 9, 2021
Cash Dividend
Ex DateEx DateNov 3, 2020
Dividend/Share
₹0.05
Ex DateEx Date
Nov 3, 2020
Profit before tax (PBT) fell 5.46% YoY to Rs 29.25 crore during the quarter. Total expenses fell 5% to Rs 175.04 crore in Q2 FY25 as compared with Rs 184.26 crore in Q2 FY24. Cost of material consumed stood at Rs 74.93 crore (down 21.36% YoY), employee benefit expenses stood at Rs 28.47 crore (up 6.31% YoY), finance cost was at Rs 5.17 crore (up 15.92% YoY) during the period under review. EBITDA stood at Rs 38.7 crore in Q2 FY25, registering the de-growth of 2.52% as compared with Rs 39.7 crore in Q2 FY24. EBITDA margin increased 18.95% in Q2 FY25 as compared with18.47% in Q2 FY24. Gufic Biosciences is a pharmaceutical company engaged in research and development, manufacturing, marketing, distribution, and sale of pharmaceutical and herbal products. Its products include a wide range of active pharmaceutical ingredients (APIs). Gufic is a leading manufacturer of lyophilized injections, boasting a fully automated lyophilization plant.Powered by Capital Market - Live
Profit before tax (PBT) fell 5.46% YoY to Rs 29.25 crore during the quarter. Total expenses fell 5% to Rs 175.04 crore in Q2 FY25 as compared with Rs 184.26 crore in Q2 FY24. Cost of material consumed stood at Rs 74.93 crore (down 21.36% YoY), employee benefit expenses stood at Rs 28.47 crore (up 6.31% YoY), finance cost was at Rs 5.17 crore (up 15.92% YoY) during the period under review. EBITDA stood at Rs 38.7 crore in Q2 FY25, registering the de-growth of 2.52% as compared with Rs 39.7 crore in Q2 FY24. EBITDA margin increased 18.95% in Q2 FY25 as compared with18.47% in Q2 FY24. Gufic Biosciences is a pharmaceutical company engaged in research and development, manufacturing, marketing, distribution, and sale of pharmaceutical and herbal products. Its products include a wide range of active pharmaceutical ingredients (APIs). Gufic is a leading manufacturer of lyophilized injections, boasting a fully automated lyophilization plant. The scrip rose 1.95% o settle at Rs 446.65 on Thursday, 14 November 2024, the domestic stock market to remain closed today on account of Guru Nanak Jayanti.Powered by Capital Market - Live
Net profit of Gufic BioSciences declined 6.16% to Rs 21.78 crore in the quarter ended September 2024 as against Rs 23.21 crore during the previous quarter ended September 2023. Sales declined 4.98% to Rs 204.18 crore in the quarter ended September 2024 as against Rs 214.87 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales204.18214.87 -5 OPM %18.9218.32 - PBDT33.5735.24 -5 PBT29.2730.94 -5 NP21.7823.21 -6 Powered by Capital Market - Live
Gufic BioSciences will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live
Gufic BioSciences announced that the Annual General Meeting (AGM) of the company will be held on 25 September 2024.Powered by Capital Market - Live
Net profit of Gufic BioSciences rose 1.16% to Rs 20.86 crore in the quarter ended June 2024 as against Rs 20.62 crore during the previous quarter ended June 2023. Sales rose 3.99% to Rs 202.81 crore in the quarter ended June 2024 as against Rs 195.02 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales202.81195.02 4 OPM %17.6518.19 - PBDT32.4232.29 0 PBT28.1128.05 0 NP20.8620.62 1 Powered by Capital Market - Live
Gufic BioSciences will hold a meeting of the Board of Directors of the Company on 14 August 2024.Powered by Capital Market - Live
Board of Gufic BioSciences approves change in directorate
Gufic Biosciences hits 52-week high China nod to anaesthesia API
Stocks that will see action today: June 19, 2023
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant